Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P648: Clinical feasibility of dried blood sampling for infliximab in IBD patientsECCO '18 Vienna
Year: 2018
Authors:

S. Berends1,2*, G. D'Haens2, K. Bloem3,4, J. Schaap4, A. De Vries4, T. Rispens3,4, R. Mathôt1

1Academic Medical Center (AMC), Hospital Pharmacy, Amsterdam, The Netherlands, 2Academic Medical Center (AMC), Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3Sanquin Research and Landsteiner Laboratory, Immunopathology, Amsterdam, The Netherlands, 4Sanquin Diagnostic Services, Biologicals Lab, Amsterdam, The Netherlands

P649: Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patientsECCO '18 Vienna
Year: 2018
Authors:

J.C. Marini1, A. Gils2*, G. Shankar1, M. Peeters2, E. Brouwers2, P. van Iperen3, M. Le Bars4, G.S. Bevalander3, B. Sattin5, S. Sloan6

1Janssen Research and Development, LLC, Spring House, PA, USA, 2KU Leuven, Leuven, Belgium, 3Janssen-Cilag BV, Breda, The Netherlands, 4Janssen-Cilag, Issy-les-Moulineaux, France, 5Janssen Inc., Toronto, Canada, 6Janssen Research and Development, LLC, Raritan, NJ, USA

P650: Combination therapy for perianal fistulising Crohn’s disease in biological era: What is the optimal time for surgical intervention?ECCO '18 Vienna
Year: 2018
Authors:

P. Zhu, B.L. Yang*

Affiliated Hospital of Nanjing University of Chinese Medicine, Colon and Rectal Surgery, NANJING, China

P651: Reliability of blood tests, neutrophil lymphocyte ratio (NLR) and Glasgow prognostic index (GPI) to evaluate the severity of the Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

E.O. Gur1*, S. Karaisli1, O.N. Dilek1, T. Acar1, S. Haciyanli1, B. Unsal2, M. Haciyanli1

1Katip Celebi University Ataturk Training and Research Hospital, General Surgery, Izmr, Turkey, 2Katip Celebi University Ataturk Training and Research Hospital, Gastroenterology, Izmr, Turkey

P652: Nutritional adequacy of popular defined diets for inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

N. Nazarenkov1, L. Beeken2, K. Seeger2, A. Ananthakrishnan3, H. Khalili3, J. Lewis4, G. Konijeti2,5*

1University of California, Davis, Davis, USA, 2Scripps Clinic, Division of Gastroenterology, La Jolla, USA, 3Massachusetts General Hospital, Division of Gastroenterology, Boston, USA, 4University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, USA, 5The Scripps Research Institute, Scripps Translational Science Institute, La Jolla, USA

P653: Impact of ileostomy on recurrence rate after ileo-colic resection for Crohn’s disease: A critical appraisal from a referral centreECCO '18 Vienna
Year: 2018
Authors:

B. Sensi1, S. D'Ugo1,2*, G. Bagaglini1, A. Di Giorgio1, L. Fazzolari1, G. Sica1

1Tor Vergata University, Department of Surgery, Rome, Italy, 2Tor Vergata University, Surgery, Rome, Italy

P654: Advances in optimalisation of therapeutic drug monitoring using mucosal TNF expression and anti-TNF concentration in patients with inflammatory bowel disease treated with biologicals: Preliminary results from a single-centre studyECCO '18 Vienna
Year: 2018
Authors:

K. Farkas1*, G. Elekes1, D. Kata2, I. Földesi2, S. Lada1, T. Ferenci3, T. Madácsy1, M. Rutka1, A. Bálint1, R. Bor1, A. Fábián1, A. Milassin1, Z. Szepes1, F. Nagy1, J. Maléth1, T. Molnár1

1University of Szeged, 1st Department of Medicine, Szeged, Hungary, 2University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary, 3Physiological Controls Research Center, Óbuda University, Budapest, Hungary

P655: Immunogenicity after transition from adalimumab to ABP 501 in patients with plaque psoriasisECCO '18 Vienna
Year: 2018
Authors:

D. Mytych*, J. Miller, M. Starcevic Manning, I. Wala, H. Wang, N. Zhang, E. Krishnan, A. Kaliyaperumal

Amgen Inc., Biosimilars, Thousand Oaks, USA

P656: Are trough levels of anti-TNF drugs related with treatment failure and duration of treatment?ECCO '18 Vienna
Year: 2018
Authors:

J. Gonzalez-Lopez1, C. Llamas2, J.M. Giráldez-Montero1, R. Ferreiro3, I. Baston3, M.J. Lamas1, J.E. Dominguez-Munoz3, M. Barreiro-de Acosta3*

1University Hospital Santiago, Department of Pharmacy, Santiago, Spain, 2USC Student, Santiago, Spain, 3University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain

P657: Postoperative outcome in Crohn’s disease: Observational study of 1283 surgical patientsECCO '18 Vienna
Year: 2018
Authors:

D. Zambonin1*, E. Lavorini1, F. Giudici1, F. Ficari1, S. Bagnoli2, S. Scaringi3

1University of Florence, Florence, Italy, 2Division of Gastroenterology, AOU Careggi Hospital, Florence, Italy, 3Digestive Surgery Unit, Careggi University Hospital, Florence, Italy

P658: Faecal calprotectin is capable of predicting mucosal healing in paediatric-onset Crohn’s disease patients under sustained clinical remission with biologicsECCO '18 Vienna
Year: 2018
Authors:

B. Kang1, J.Y. Kim1, K. Lee2, B.-H. Choe1, Y.H. Choe2*

1Kyungpook National University Hospital, Daegu, South Korea, 2Samsung Medical Center, Seoul, South Korea

P659: FMT as a treatment for IBD: A national survey of gastroenterologists in the UKECCO '18 Vienna
Year: 2018
Authors:

J. McIlroy1*, N. Nalagatla1, R. Hansen2, A. Hart3, G. Hold1,4

1University of Aberdeen, School of Medicine and Dentistry, Aberdeen, UK, 2Glasgow Royal Hospital for Sick Children, Department of Paediatric Gastroenterology, Hepatology and Nutrition, Glasgow, UK, 3St Mark's Hospital, Department of IBD, London, UK, 4University of New South Wales, Department of Gastroenterology, Sydney, Australia

P660: A pilot elastography study in patients with inflammatory bowel disease on long-term treatment with azathioprineECCO '18 Vienna
Year: 2018
Authors:

G.J. Mantzaris*, C. Hatzievagelinou, G. Karampekos, G. Filippidis, F. Gkeros, I. Tziortziotis, M. Vraka, A. Christidou, M. Mela, N. Viazis P. Rivière1,2*, S. Vermeire1, M. Irles-Depe2, G. Van Assche1, P. Rutgeerts1, A. de Buck van Overstraeten1, Q. Denost3, A. Wolthuis1, A. D'Hoore1, D. Laharie2, M. Ferrante1

Evangelismos Hospital, Gastroenterology Department, Athens, Greece 1University Hospitals Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2Haut-Lévêque Hospital, CHU de Bordeaux, Department of Hepatogastroenterology and Digestive Oncology, Bordeaux, France, 3Haut-Lévêque Hospital, CHU de Bordeaux, Department of Abdominal Surgery, Bordeaux, France

P662: Transmural healing evaluated by magnetic resonance enterography in paediatric Crohn’s disease patients under maintenance treatment with biologicsECCO '18 Vienna
Year: 2018
Authors:

B. Kang1, S. Oh2, T.Y. Jeon2, Y.H. Choe2*

1Kyungpook National University Hospital, Daegu, South Korea, 2Samsung Medical Centre, Seoul, South Korea

P663: Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registryECCO '18 Vienna
Year: 2018
Authors:

F. Cañete1,2*, M. Mañosa2,3, M.J. Casanova3,4, R.C. González-Sueyro5, J. Barrio6, F. Bermejo7, P. Nos8, E. Iglesias9, E. Garcia-Planella10, J.L. Perez-Calle11, L. Ramos12, R. De Francisco13, M. Rivero14, A. Montserrat3,15, P. Navarro16, C. Taxonera17, J. Hinojosa18, A. Núñez19, M. Navarro-Llavat20, P. Ramírez-de la Piscina21, L. Fernández22, P. Almela23, R. Ríos24, A. Clos2, E. Cabré2,3, E. Domènech2,3

1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona - Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Department of Gastroenterology, Badalona - Barcelona, Spain, 3CIBEREHD, Madrid, Spain, 4Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 5Hospital Universitari Clínic, Gastroenterology, Barcelona, Spain, 6Hospital Rio Hortegea, Gastroenterology, Valladolid, Spain, 7Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain, 8Hospital Politècnic La Fe, Gastroenterology, Valencia, Spain, 9Hospital Reina Sofía, Cordoba, Spain, 10Hospital santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 11Hospital Universitario Fundación Alcorcón, Gastroenterology, Alcorcón, Spain, 12Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain, 13Hospital Central de Asturias, Gastroenterology, Oviedo, Spain, 14Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain, 15Hospital Parc Taulí, Gastroenterology, Sabadell, Spain, 16Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain, 17Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 18Hospital de Manises, Gastroenterology, Valencia, Spain, 19Hospital Universitario de Salamanca, Gastroenterology, Salamanca, Spain, 20Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain, 21Hospital Universitario Araba, Gastroenterology, Vitoria, Spain, 22Hospital Clínico Universitario, Gastroenterology, Valladolid, Spain, 23Hospital General de Castellón, Gastroenterology, Castellón, Spain, 24Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain

P664: Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumabECCO '18 Vienna
Year: 2018
Authors:

J. Berthaux1, P. DeBoissieu1, A. Amiot2, T. Vaysse1, F. Carbonnel1, M. Collins1*

1CHU Kremlin-Bicêtre, Kremlin Bicêtre, France, 2CHU Henri Mondor, Creteil, France

P665: Higher BMI but not systemic immune suppression increases the risk of short-term postoperative complications in Crohn’s disease patientsECCO '18 Vienna
Year: 2018
Authors:

D. Podmanicky1*, V. Bak1, M. Krizko2, Z. Zelinkova2

1St Michael’s Hospital, Department of Surgery, Bratislava, Slovakia, 2St Michael’s Hospital, Department of Gastroenterology, Bratislava, Slovakia

P666: Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA RegistryECCO '18 Vienna
Year: 2018
Authors:

M. Chaparro1,2,3,4*, A. Garre1,2,3,4, I. Alfaro4,5, M. Iborra4,6, P. Mesonero7, I. Vera Mendoza8, A. Rodríguez9, J. Miquel-Cusachs10, S. Riestra11, P. Navarro12, L. De Castro Parga13, C. González-Muñoza14, M. Rivero Tirado15, M. Mañosa4,16, L. Fernández Salazar17, M. García-Sepulcre18, J. Guardiola19, J. Cabriada20, A. Gutiérrez Casbas4,21, B. Sicilia22, J.L. Pérez Calle23, M. Piqueras24, I. Guerra25, O. Roncero26, M. Navarro-Llavat27, E. Sainz28, J. Barrio29, X. Calvet4,30, A. García31, M. Llorente Barrio32, R. Lorente33, P. Almela34, R. Madrigal35, A.J. Lucendo Villarín36, R. Pajares37, M. Van Domselaar38, J. Legido Gil39, J.P. Gisbert1,2,3,4

1Hospital Universitario de La Princesa, Gastroenterology Unit, Madrid, Spain, 2Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain, 3Universidad Autónoma de Madrid, Madrid, Spain, 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, 5Hospital Clínico y Provincial de Barcelona, Gastroenterology Unit, Barcelona, Spain, 6Hospital Universitario y Politécnico de La Fe, Gastroenterology Unit, Valencia, Spain, 7Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain, 8Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Madrid, Spain, 9Hospital Universitario De Salamanca, Gastroenterology Unit, Salamanca, Spain, 10Hospital Universitario de Gerona Dr Josep Trueta, Gastroenterology Unit, Gerona, Spain, 11Hospital Universitario Central de Asturias, Gastroenterology Unit, Oviedo, Spain, 12Hospital Clínico Universitario de Valencia, Gastroenterology Unit, Valencia, Spain, 13Complejo Hospitalario Universitario de Vigo, Gastroenterology Unit, Vigo, Spain, 14Hospital de La Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain, 15Hospital Universitario de Marqués de Valdecilla, Gastroenterology Unit, Santander, Spain, 16Hospital Universitario Germans Trias i Pujol, Gastroenterology Unit, Badalona, Spain, 17Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain, 18Hospital General Universitario de Elche, Gastroenterology Unit, Elche, Spain, 19Hospital Universitario de Bellvitge, Gastroenterology Unit, Hospitalet de Llobregat, Spain, 20Hospital de Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain, 21Hospital General Universitario de Alicante, Gastroenterology Unit, Alicante, Spain, 22Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain, 23Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Alcorcón, Spain, 24Consorci Sanitari Terrassa, Gastroenterology Unit, Tarrasa, Spain, 25Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Fuenlabrada, Spain, 26Complejo Hospitalario la Mancha Centro, Gastroenterology Unit, Alcázar de San Juan, Spain, 27Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology Unit, Sant Joan Despí, Spain, 28Hospital Universitario Arnau de Vilanova, Gastroenterology Unit, Lérida, Spain, 29Hospital Universitario Rio Hortega, Gastroenterology Unit, Valladolid, Spain, 30Consorcio Corporación Sanitaria Parc Taulí, Gastroenterology Unit, Sabadell, Spain, 31Hospital Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain, 32Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain, 33Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain, 34Hospital General Universitario de Castellón, Gastroenterology Unit, Castellón, Spain, 35Complejo Hospitalario de Palencia, Gastroenterology Unit, Palencia, Spain, 36Hospital Público General de Tomelloso, Gastroenterology Unit, Tomelloso, Spain, 37Hospital Universitario Infanta Sofía, Gastroenterology Unit, San Sebastián de los Reyes, Spain, 38Hospital Universitario de Torrejón, Gastroenterology Unit, Torrejón de Ardoz, Spain, 39Hospital General de Segovia, Gastroenterology Unit, Segovia, Spain

P667: Standard vs. intensified infliximab rescue therapy for hospitalised paediatric patients with acute severe exacerbations of colitis-predominant inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

K.S. Singh1*, L. Hart2, A. Al Khoury1, C.-Y. Chao2,3, W. Afif2, P.L. Lakatos2, N. Ahmed4, T. Bessissow2

1McGill University, Department of Medicine, Montreal, Canada, 2McGill University, Division of Gastroenterology – Department of Medicine, Montreal, Canada, 3Princess Alexandra Hospital, Division of Gastroenterology and Hepatology, Brisbane, Australia, 4McGill University, Division of Gastroenterology – Department of Paediatrics, Montreal, Canada

P668: Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBDECCO '18 Vienna
Year: 2018
Authors:

S. Nurbhai1*, M. West1, T. MacDonald2, G. Parkes3, P. Irving4, A. Vossenkaemper2, S. Crowe1

1VHsquared Ltd., Cambridge, UK, 2QMUL, Blizard Institute, London, UK, 3Royal London Hospital Bart’s Health NHS Trust, London, UK, 4Guys and St Thomas' Hospital, London, UK